Treatment of lethal midline granuloma type nasal T-cell lymphoma.
Nasal T-cell lymphoma of the LMG type (LMG-NTL) is characterized by progressive, unrelenting ulceration, and necrosis of the nasal cavity and midline facial tissues. The clinical behavior of this tumor in 16 patients is compared with that of a nasal lymphoma of non-LMG-NTL type (non-LMG-NTL) in 8 patients and a paranasal sinus lymphoma (PSL) in 6 patients. All patients had stage I or II disease. Fourteen of the 16 patients with LMG-NTL received chemotherapy before and/or after radiotherapy. Cause-specific 5-year survival rates for patients with LMG-NTL, non-LMG-NTL, and PSL were 22%, 75%, and 67% respectively. Seven patients with LMG-NTL, had complete response, although 3 recurred, whereas it was incomplete in 9 patients. The data indicates that it is desirable to deliver 50 Gy or more to achieve in-field control of LMG-NTL.
Sakata
K
K
Department of Radiology, Sapporo Medical University, School of Medicine, Chuo-Ku, Japan.
Hareyama
M
M
Ohuchi
A
A
Sido
M
M
Nagakura
H
H
Morita
K
K
Harabuchi
Y
Y
Kataura
A
A
D000328:Adult; D000368:Aged; D005260:Female; D005500:Follow-Up Studies; D006103:Granuloma, Lethal Midline / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans; D016399:Lymphoma, T-Cell / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009669:Nose Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D009626:Terminology as Topic